Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health system.

Carlos BalmacedaManuel Antonio EspinozaTomas AbbottAnne Peters

Published in: Expert review of pharmacoeconomics & outcomes research (2022)

FF/UMEC/VI appears to be a cost-effective intervention for treating COPD compared to FF/VI. However, FF/UMEC/VI compared to FP/SAL/TIO showed an ICER above the threshold of 1 GDPpc, but, in comparison with lower price, the ICER was below 3 GDPpc.

Keyphrases

chronic obstructive pulmonary disease
lung function
randomized controlled trial
healthcare
early onset
high intensity
air pollution
adverse drug
replacement therapy